Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (KCSG-LU08-01)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sun, Jong-Mu | - |
dc.contributor.author | Lee, Ki Hyeong | - |
dc.contributor.author | Kim, Sang-we | - |
dc.contributor.author | Lee, Dae Ho | - |
dc.contributor.author | Min, Young Joo | - |
dc.contributor.author | Yun, Hwan Jung | - |
dc.contributor.author | Kim, Hoon Kyo | - |
dc.contributor.author | Song, Hong Suk | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.contributor.author | Kim, Bong-Seog | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Lee, Keehyun | - |
dc.contributor.author | Jo, Sook Jung | - |
dc.contributor.author | Lee, Jae Won | - |
dc.contributor.author | Ahn, Jin Seok | - |
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.date.accessioned | 2021-09-06T11:57:04Z | - |
dc.date.available | 2021-09-06T11:57:04Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2012-12-15 | - |
dc.identifier.issn | 0008-543X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106654 | - |
dc.description.abstract | BACKGROUND: Gefitinib was compared with pemetrexed as second-line therapy in a clinically selected population previously treated with platinum-based chemotherapy. METHODS: A phase 3 trial of gefitinib (250 mg/day) versus pemetrexed (500 mg/m(2) on day 1, every 3 weeks) was conducted in patients who had never smoked and who had advanced pulmonary adenocarcinoma treated with 1 previous platinum-based regimen. The primary endpoint was progression-free survival (PFS). RESULTS: A total of 135 patients were analyzed. The gefitinib group had significantly longer PFS compared with the pemetrexed group, with a median PFS time of 9.0 versus 3.0 months (P = .0006). The objective response rates were 58.8% and 22.4% for gefitinib and pemetrexed, respectively (P < .001). However, there was no statistically significant difference in overall survival between the 2 groups (22.2 vs 18.9 months; P = .37). The difference of PFS was increased in a subgroup analysis of 33 patients with activating epidermal growth factor receptor mutation (15.7 vs 2.9 months; hazard ratio, 0.3; 95% confidence interval, 0.13-0.72; P = .005), with numerical superiority of gefitinib in the 38 patients testing negative for epidermal growth factor receptor mutation (5.9 vs 2.7 months; P = .099). Both regimens were well tolerated. There were no significantly different changes in quality of life between the 2 groups, except that symptom scores for dyspnea and diarrhea favored the gefitinib and pemetrexed arms, respectively. CONCLUSIONS: Gefitinib showed superior efficacy to pemetrexed as second-line therapy in Korean never-smokers with pulmonary adenocarcinoma. Cancer 2012; 118:6234-42. (C) 2012 American Cancer Society. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.subject | PHASE-III TRIAL | - |
dc.subject | CLINICAL-TRIALS | - |
dc.subject | NAIVE PATIENTS | - |
dc.subject | NEVER-SMOKERS | - |
dc.subject | EGFR | - |
dc.subject | ADENOCARCINOMA | - |
dc.subject | DOCETAXEL | - |
dc.subject | MUTATIONS | - |
dc.subject | GEMCITABINE | - |
dc.subject | ERLOTINIB | - |
dc.title | Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (KCSG-LU08-01) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Jae Won | - |
dc.identifier.doi | 10.1002/cncr.27630 | - |
dc.identifier.scopusid | 2-s2.0-84870688172 | - |
dc.identifier.wosid | 000311911600029 | - |
dc.identifier.bibliographicCitation | CANCER, v.118, no.24, pp.6234 - 6242 | - |
dc.relation.isPartOf | CANCER | - |
dc.citation.title | CANCER | - |
dc.citation.volume | 118 | - |
dc.citation.number | 24 | - |
dc.citation.startPage | 6234 | - |
dc.citation.endPage | 6242 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | NAIVE PATIENTS | - |
dc.subject.keywordPlus | NEVER-SMOKERS | - |
dc.subject.keywordPlus | EGFR | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | ERLOTINIB | - |
dc.subject.keywordAuthor | gefitinib | - |
dc.subject.keywordAuthor | pemetrexed | - |
dc.subject.keywordAuthor | nonsmall cell lung cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.